

Upendra Rathore

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7975106/publications.pdf>

Version: 2024-02-01

11
papers

165
citations

1307594

7
h-index

1474206

9
g-index

11
all docs

11
docs citations

11
times ranked

93
citing authors

#	ARTICLE	IF	CITATIONS
1	A systematic review of clinical and preclinical evidences for Janus kinase inhibitors in large vessel vasculitis. <i>Clinical Rheumatology</i> , 2022, 41, 33-44.	2.2	23
2	The prevalence and clinical characteristics of anti-HMGCR (anti-3-hydroxy-3-methyl-glutaryl-coenzyme) Tj ETQq0 0 0 rgBT /Overlock 10 T <i>Rheumatology International</i> , 2022, 42, 1143-1154.	3.0	4
3	Novel Th17 Lymphocyte Populations, Th17.1 and PD1+Th17, are Increased in Takayasu Arteritis, and Both Th17 and Th17.1 Sub-Populations Associate with Active Disease. <i>Journal of Inflammation Research</i> , 2022, Volume 15, 1521-1541.	3.5	21
4	Scalp calcinosis in juvenile dermatomyositis. <i>Rheumatology</i> , 2021, 60, 1569-1569.	1.9	1
5	Disease-modifying antirheumatic drugs for the management of takayasu arteritis â€œ Protocol for a systematic review. <i>Indian Journal of Rheumatology</i> , 2021, 16, 79.	0.4	1
6	Disease-modifying anti-rheumatic drugs for the management of Takayasu arteritisâ€”a systematic review and meta-analysis. <i>Clinical Rheumatology</i> , 2021, 40, 4391-4416.	2.2	53
7	Corticosteroid monotherapy for the management of Takayasu arteritisâ€”a systematic review and meta-analysis. <i>Rheumatology International</i> , 2021, 41, 1729-1742.	3.0	22
8	Patient-Reported Outcome Measures in Takayasu Arteritis: A Systematic Review and Meta-Analysis. <i>Rheumatology and Therapy</i> , 2021, 8, 1073-1093.	2.3	14
9	Characteristics and outcomes of overlap myositis: a comparative multigroup cohort study in adults from the MyoCite cohort. <i>Rheumatology International</i> , 2021, 41, 551-563.	3.0	12
10	Management of Takayasu arteritis: The elusive search for the holy grail!. <i>Indian Journal of Rheumatology</i> , 2021, 16, 373.	0.4	0
11	Psoriasiform rashes as the first manifestation of anti-MDA5 associated myositis. <i>Rheumatology</i> , 2020, 60, 3483.	1.9	14